CHDI and Siena Biotech SpA Enter Collaboration to Validate Novel Therapeutic Targets for Huntington’s Disease
News Mar 23, 2011
CHDI Foundation, Inc. (CHDI) and Siena Biotech SpA have announced a collaboration to explore and validate molecular targets that could have therapeutic potential in Huntington’s disease (HD).
CHDI, a not-for-profit research organization that is exclusively dedicated to rapidly discovering and developing therapies that slow the progression of HD, will partner equally with Siena Biotech, an innovative drug discovery company whose primary focus is on degenerative and proliferative diseases of the central nervous system, including HD, with the aim of discovering new drugs for therapeutic intervention.
“Siena Biotech is already committed to Huntington’s disease as a fundamental part of their portfolio, and we’re very excited to be able to draw on their neurological drug development expertise and their state-of-the-art laboratory infrastructure,” said Robert Pacifici, Chief Scientific Officer of CHDI. “Our new collaboration will initially focus on validating potential therapeutic targets that modulate post-translational modification of mutant huntingtin, and we hope this will mature into a full-fledged joint drug discovery program.”
“Our collaboration with CHDI will create a synergy between our two organization’s strengths that will accelerate progress towards our common goal of developing new therapies for Huntington’s disease, an objective to which both Siena Biotech and CHDI are fully dedicated” said Giovanni Gaviraghi, Chief Executive Officer of Siena Biotech.
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE